Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 11802115 Pharmaceutical formulation of odevixibat

Patent 11802115 was granted and assigned to Albireo AB on October, 2023 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
‌
Albireo AB
Date Filed
June 20, 2019
Date of Patent
October 31, 2023
Patent Applicant
‌
Albireo AB
Patent Application Number
16477160
Patent Citations
‌
US Patent 7192945 Benzothiazepine derivatives
‌
US Patent 7192946 Benzothiazepine derivatives
‌
US Patent 7192947 Peptides derivatives comprising thiazepine group for the treatment of hyperlipidemic conditions
‌
US Patent 6906058 1,5-Benzothiazepines and their use as hypolipidaemics
‌
US Patent 6943189 Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG CO-A reductase inhibitors
‌
US Patent 7125864 Benzothiazepine derivatives for the treatment of hyperlipidemia
‌
US Patent 7132416 Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia
‌
US Patent 7132557 Amine compounds and curable compositions derived therefrom
‌
US Patent 10183920 Crystal modifications of elobixibat
‌
US Patent 10428109 Process for the preparation of 1,5-benzothiazepine compounds
•••
Patent Inventor Names
Anna-Maria Tivert
Robert Lundqvist
Ann-Charlotte Dahlquist
Jessica Elversson
Ingvar Ymen
Martin Bohlin
Eva Byröd
Nils Ove Gustafsson
Per-Göran Gillberg
Rikard Bryland
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
11802115
Patent Primary Examiner
‌
Bethany P Barham

Find more entities like US Patent 11802115 Pharmaceutical formulation of odevixibat

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo